جميع الدراسات
التوظيفالمرحلة 3تدخلي

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

This research study is about a new medicine called orforglipron for young people, aged 10 to 17, who have type 2 diabetes. We want to find out how well this new medicine works compared to another common medicine for type 2 diabetes, called dulaglutide. The study will also carefully check if the medicines are safe to use and how the body handles them. Taking part in this study would involve regular check-ups and last for about 61 weeks, which is just over a year. The main goal is to find better ways to help young people manage their type 2 diabetes.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 3
الراعي
شركة إيلي ليلي وشركاه
الهدف من التسجيل
170
ابدأ
08 Jul 2026
التاريخ المتوقع للانتهاء
01 مارس 2030

ما هو موضوع هذه الدراسة؟

Type 2 diabetes is a condition where your body doesn't use sugar properly, leading to high blood sugar levels. It's often managed with diet, exercise, and medicines. This study focuses on young people, aged between 10 and 17 years old, who have type 2 diabetes. We are particularly interested in a new medicine called orforglipron. We want to learn if it's an effective and safe treatment option for this age group.

To understand how well orforglipron works, we're comparing it to another medicine, dulaglutide, which is already used for type 2 diabetes. The study will look closely at how these medicines affect blood sugar levels, if they have any side effects, and how they behave inside the body. Your involvement could help doctors understand more about treating type 2 diabetes in young people.

The information gathered from this study is really important. It helps healthcare professionals decide on the best treatments for young people with type 2 diabetes now and in the future. By participating, you could contribute to medical knowledge and potentially help many others facing similar challenges.

النقاط الرئيسية

  • This study is testing a new medicine for young people aged 10-17 with type 2 diabetes.
  • It compares the new medicine (orforglipron) with an existing one (dulaglutide).
  • The study lasts about 61 weeks and involves regular clinic visits.
  • Participation helps future medical understanding of type 2 diabetes in young people.
  • يمكنك الانسحاب من الدراسة في أي وقت دون التأثير على رعايتك.

من قد يكون مؤهلاً؟

To join this study, participants must be between 10 and 17 years old and have type 2 diabetes. You would need to be managing your diabetes with diet and exercise, and also be taking metformin and/or a type of insulin called basal insulin. Your recent blood test (HbA1c) should show your average blood sugar levels are between 6.5% and 11.0%. Also, you should weigh at least 50 kilograms (about 7 stone 12 pounds) and have a body mass index (BMI) that's considered higher for your age.

There are also some reasons why you might not be able to join. For example, if you have type 1 diabetes instead of type 2, or if you've had severe problems like diabetic ketoacidosis (a serious complication of diabetes) in the past. If you've had issues with very low blood sugar that you couldn't feel (hypoglycemic unawareness) or severe low blood sugar recently, you wouldn't be able to take part.

Other reasons for not being able to join include a history of certain conditions like pancreatitis or gallbladder disease, or a personal or family history of specific types of thyroid cancer. Also, if you've taken certain other diabetes medicines or weight-loss drugs within the last 3 months, you wouldn't be eligible.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Are you between 10 and 17 years old?
  2. Do you have type 2 diabetes?
  3. Are you currently taking metformin and/or basal insulin?
  4. Do you weigh at least 50 kilograms (about 7 stone 12 pounds)?
  5. Have you *not* had severe low blood sugar or an inability to feel low blood sugar recently?
  6. Do you have no history of certain conditions like pancreatitis or specific thyroid cancers?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, it will last for about 61 weeks, which is just over a year. During this time, you will have regular visits to the clinic for health check-ups and assessments. These visits will help us monitor your health, how the medicine is working, and if you have any side effects.

You'll be given either the new medicine, orforglipron, or the existing medicine, dulaglutide, to take regularly as instructed. There will be blood tests and other examinations to see how your body is responding to the treatment. You'll also be asked to keep track of certain information at home.

Throughout the study, the research team will be there to support you and answer any questions you have. Even if you join, you are always free to decide to leave the study at any time, for any reason, without it affecting your medical care.

المخاطر والفوائد المحتملة

Taking part in a study like this might offer some potential benefits, such as receiving a new or existing medicine for your type 2 diabetes and having close medical monitoring. However, there are also potential risks, including possible side effects from the medicines. The research team will explain all known risks to you before you agree to participate. You have the right to withdraw from the study at any time without having to give a reason, and this decision will not affect your usual medical care.

المواقع (71)

  • Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology
    الرمز البريدي المؤكد
    ساكرامنتو، الولايات المتحدة· التوظيف
  • مستشفى رادي للأطفال
    الرمز البريدي المؤكد
    سان دييغو، الولايات المتحدة· لم يبدأ التوظيف بعد
  • Stamford Therapeutics Consortium
    الرمز البريدي المؤكد
    Stamford, United States· التوظيف
  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics (CAP)
    الرمز البريدي المؤكد
    أتلانتا، الولايات المتحدة· لم يبدأ التوظيف بعد
  • CenExel iResearch, LLC
    الرمز البريدي المؤكد
    Decatur, United States· التوظيف
  • Medical Research Partners
    الرمز البريدي المؤكد
    Ammon, United States· التوظيف
  • Cotton O'Neil Diabetes & Endocrinology
    الرمز البريدي المؤكد
    Topeka, United States· التوظيف
  • SUNY Upstate Medical University
    الرمز البريدي المؤكد
    سيراكيوز، الولايات المتحدة· لم يبدأ التوظيف بعد
  • Advantage Clinical Trials
    الرمز البريدي المؤكد
    ذا برونكس، الولايات المتحدة· التوظيف
  • Central States Research
    الرمز البريدي المؤكد
    Tulsa, United States· التوظيف
  • Frontier Clinical Research, LLC
    الرمز البريدي المؤكد
    Smithfield, United States· التوظيف
  • Vanderbilt Health One Hundred Oaks
    الرمز البريدي المؤكد
    ناشفيل، الولايات المتحدة· لم يبدأ التوظيف بعد

أسئلة شائعة

What is Type 2 Diabetes?

Type 2 diabetes is a condition where your body struggles to use sugar (glucose) for energy properly, leading to high sugar levels in your blood.

What is an 'HbA1c' blood test?

HbA1c is a simple blood test that shows your average blood sugar levels over the past 2 to 3 months. It's a common way to see how well diabetes is being managed.

ماذا يعني 'المرحلة 3' لدراسة ما؟

Phase 3 means the medicine has already been tested in smaller groups and is now being studied in a larger group of people to confirm its effectiveness, monitor side effects, and compare it to existing treatments.

هل سأعرف إذا كنت سأحصل على الدواء الجديد أم الدواء الحالي؟

In many studies like this, participants are randomly assigned to receive one of the medicines, and sometimes neither you nor the doctors know which one you are getting. This helps make the study as fair as possible.

ماذا لو غيرت رأيي بعد الانضمام؟

You are free to leave the study at any time, for any reason, without it affecting your regular medical care. Your decision will be fully respected.

كيفية معرفة المزيد

أسئلة التجارب أو أسئلة المشاركة: 1-877-CTLILLY (1-877-285-4559) أو

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Study of Orforglipron (LY3502970) Compared With Dulaglutid… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.